Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 4932 | 3.245 |
09:34 ET | 5973 | 3.22 |
09:36 ET | 13770 | 3.19 |
09:38 ET | 6988 | 3.19 |
09:39 ET | 13577 | 3.2 |
09:41 ET | 100 | 3.175 |
09:43 ET | 1782 | 3.18 |
09:45 ET | 2700 | 3.165 |
09:48 ET | 3571 | 3.14 |
09:50 ET | 200 | 3.135 |
09:52 ET | 850 | 3.135 |
09:54 ET | 1187 | 3.1196 |
09:56 ET | 1411 | 3.118 |
09:57 ET | 1399 | 3.12 |
09:59 ET | 1099 | 3.12 |
10:01 ET | 5555 | 3.125 |
10:03 ET | 800 | 3.13 |
10:08 ET | 2200 | 3.14 |
10:10 ET | 1000 | 3.138 |
10:12 ET | 1031 | 3.1368 |
10:14 ET | 650 | 3.1309 |
10:15 ET | 1000 | 3.1362 |
10:17 ET | 6373 | 3.155 |
10:21 ET | 500 | 3.158 |
10:24 ET | 1381 | 3.155 |
10:26 ET | 200 | 3.155 |
10:28 ET | 200 | 3.1564 |
10:30 ET | 3400 | 3.16 |
10:32 ET | 2800 | 3.16 |
10:33 ET | 800 | 3.16 |
10:37 ET | 300 | 3.165 |
10:39 ET | 1200 | 3.15 |
10:42 ET | 500 | 3.15 |
10:44 ET | 100 | 3.145 |
10:46 ET | 297 | 3.1491 |
10:48 ET | 400 | 3.14 |
10:50 ET | 100 | 3.14 |
10:53 ET | 100 | 3.14 |
10:55 ET | 2100 | 3.145 |
10:57 ET | 100 | 3.14 |
11:00 ET | 100 | 3.145 |
11:02 ET | 100 | 3.14 |
11:04 ET | 500 | 3.13 |
11:06 ET | 4091 | 3.135 |
11:08 ET | 2261 | 3.1399 |
11:11 ET | 3699 | 3.13 |
11:13 ET | 600 | 3.13 |
11:15 ET | 200 | 3.13 |
11:18 ET | 200 | 3.138 |
11:22 ET | 200 | 3.13 |
11:27 ET | 100 | 3.13 |
11:29 ET | 100 | 3.13 |
11:33 ET | 100 | 3.13 |
11:36 ET | 100 | 3.13 |
11:38 ET | 100 | 3.13 |
11:40 ET | 1700 | 3.13 |
11:42 ET | 17768 | 3.13 |
11:44 ET | 1289 | 3.13 |
11:45 ET | 200 | 3.13 |
11:47 ET | 6700 | 3.13 |
11:49 ET | 5750 | 3.13 |
11:51 ET | 1780 | 3.12 |
11:54 ET | 1350 | 3.1199 |
11:56 ET | 100 | 3.1199 |
12:00 ET | 200 | 3.115 |
12:02 ET | 100 | 3.11 |
12:03 ET | 100 | 3.11 |
12:05 ET | 6773 | 3.095 |
12:07 ET | 11035 | 3.11 |
12:09 ET | 5098 | 3.095 |
12:12 ET | 900 | 3.095 |
12:14 ET | 1792 | 3.095 |
12:16 ET | 4386 | 3.11 |
12:18 ET | 2800 | 3.105 |
12:20 ET | 2970 | 3.101 |
12:21 ET | 2300 | 3.1 |
12:23 ET | 200 | 3.1 |
12:25 ET | 404 | 3.1099 |
12:27 ET | 198 | 3.1 |
12:30 ET | 396 | 3.1 |
12:32 ET | 3245 | 3.1 |
12:34 ET | 200 | 3.1 |
12:36 ET | 6168 | 3.1099 |
12:38 ET | 8221 | 3.12 |
12:39 ET | 8269 | 3.13 |
12:41 ET | 4814 | 3.135 |
12:43 ET | 1030 | 3.13 |
12:45 ET | 545 | 3.135 |
12:48 ET | 310 | 3.135 |
12:50 ET | 837 | 3.135 |
12:52 ET | 224 | 3.135 |
12:54 ET | 213 | 3.135 |
12:56 ET | 549 | 3.135 |
12:57 ET | 410 | 3.135 |
12:59 ET | 1019 | 3.135 |
01:01 ET | 312 | 3.135 |
01:03 ET | 1666 | 3.1309 |
01:06 ET | 465 | 3.135 |
01:08 ET | 538 | 3.135 |
01:10 ET | 244 | 3.135 |
01:12 ET | 671 | 3.135 |
01:14 ET | 313 | 3.135 |
01:15 ET | 524 | 3.135 |
01:17 ET | 241 | 3.135 |
01:19 ET | 530 | 3.135 |
01:21 ET | 4701 | 3.125 |
01:24 ET | 398 | 3.125 |
01:26 ET | 846 | 3.125 |
01:28 ET | 525 | 3.125 |
01:30 ET | 1117 | 3.13 |
01:32 ET | 819 | 3.125 |
01:33 ET | 701 | 3.125 |
01:35 ET | 735 | 3.125 |
01:37 ET | 440 | 3.125 |
01:39 ET | 300 | 3.125 |
01:42 ET | 320 | 3.13 |
01:44 ET | 465 | 3.125 |
01:46 ET | 410 | 3.13 |
01:48 ET | 513 | 3.125 |
01:50 ET | 741 | 3.13 |
01:51 ET | 440 | 3.125 |
01:53 ET | 1416 | 3.13 |
01:55 ET | 2108 | 3.125 |
01:57 ET | 327 | 3.13 |
02:00 ET | 1435 | 3.125 |
02:02 ET | 445 | 3.13 |
02:04 ET | 1505 | 3.125 |
02:06 ET | 612 | 3.125 |
02:08 ET | 739 | 3.13 |
02:09 ET | 563 | 3.125 |
02:11 ET | 703 | 3.13 |
02:13 ET | 737 | 3.13 |
02:15 ET | 3934 | 3.13 |
02:18 ET | 468 | 3.125 |
02:20 ET | 235 | 3.125 |
02:22 ET | 1217 | 3.13 |
02:24 ET | 444 | 3.13 |
02:26 ET | 440 | 3.125 |
02:27 ET | 1611 | 3.13 |
02:29 ET | 846 | 3.13 |
02:31 ET | 3457 | 3.15 |
02:33 ET | 580 | 3.145 |
02:36 ET | 601 | 3.145 |
02:38 ET | 342 | 3.15 |
02:40 ET | 550 | 3.145 |
02:42 ET | 424 | 3.145 |
02:44 ET | 414 | 3.15 |
02:45 ET | 221 | 3.145 |
02:47 ET | 3986 | 3.15 |
02:49 ET | 326 | 3.145 |
02:51 ET | 37914 | 3.165 |
02:54 ET | 900 | 3.165 |
02:56 ET | 380 | 3.165 |
03:00 ET | 320 | 3.165 |
03:02 ET | 884 | 3.165 |
03:03 ET | 840 | 3.165 |
03:05 ET | 1495 | 3.165 |
03:07 ET | 900 | 3.165 |
03:09 ET | 8822 | 3.145 |
03:12 ET | 322 | 3.145 |
03:14 ET | 1366 | 3.145 |
03:16 ET | 966 | 3.145 |
03:18 ET | 329 | 3.145 |
03:20 ET | 1236 | 3.145 |
03:21 ET | 1972 | 3.15 |
03:23 ET | 803 | 3.15 |
03:25 ET | 469 | 3.145 |
03:27 ET | 809 | 3.145 |
03:32 ET | 481 | 3.145 |
03:34 ET | 491 | 3.145 |
03:36 ET | 1641 | 3.145 |
03:38 ET | 9483 | 3.17 |
03:39 ET | 383 | 3.165 |
03:43 ET | 486 | 3.165 |
03:45 ET | 4944 | 3.18 |
03:48 ET | 1455 | 3.175 |
03:50 ET | 100 | 3.175 |
03:52 ET | 2829 | 3.175 |
03:54 ET | 10678 | 3.18 |
03:56 ET | 17218 | 3.1912 |
03:57 ET | 11028 | 3.2 |
03:59 ET | 11322 | 3.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 448.9M | -12.1x | --- |
Third Harmonic Bio Inc | 564.5M | -14.7x | --- |
Altimmune Inc | 567.9M | -5.0x | --- |
enGene Holdings Inc | 572.4M | -2.8x | --- |
Olema Pharmaceuticals Inc | 550.4M | -4.9x | --- |
Oculis Holding AG | 498.8M | -6.6x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $448.9M |
---|---|
Revenue (TTM) | $9.1M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.27 |
Book Value | $0.63 |
P/E Ratio | -12.1x |
Price/Sales (TTM) | 49.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.